Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for Israeli Healthcare Professionals only

      Ubrelvy_dosing_banner

      Ubrelvy is available through the complementary insurances in three sick-funds:

      Ubrelvy_How_to_get

      To view and download the document click here:

      Download

      For more information please contact us, and our team will answer your questions

      Contact Us

      References:

      1. Ubrelvy Israel Prescribing information, July 2022. 
      2. Serrano D, Lipton RB, Scher AI, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18:101. 
      3. Blumenfeld AM, Knievel K, Adams AM, et al. Ubrogepant is safe and efficacious in participants taking concomitant preventive medication for migraine: a pooled analysis of phase 3 trials. Adv Ther. Published online December 7, 2021.

      IL-UBR-220001 | September 2022